Article thumbnail

Optimizing antibiotic selection in treating COPD exacerbations

By Attiya Siddiqi and Sanjay Sethi

Abstract

Our understanding of the etiology, pathogenesis and consequences of acute exacerbations of chronic obstructive pulmonary disease (COPD) has increased substantially in the last decade. Several new lines of evidence demonstrate that bacterial isolation from sputum during acute exacerbation in many instances reflects a cause-effect relationship. Placebo-controlled antibiotic trials in exacerbations of COPD demonstrate significant clinical benefits of antibiotic treatment in moderate and severe episodes. However, in the multitude of antibiotic comparison trials, the choice of antibiotics does not appear to affect the clinical outcome, which can be explained by several methodological limitations of these trials. Recently, comparison trials with nontraditional end-points have shown differences among antibiotics in the treatment of exacerbations of COPD. Observational studies that have examined clinical outcome of exacerbations have repeatedly demonstrated certain clinical characteristics to be associated with treatment failure or early relapse. Optimal antibiotic selection for exacerbations has therefore incorporated quantifying the risk for a poor outcome of the exacerbation and choosing antibiotics differently for low risk and high risk patients, reserving the broader spectrum drugs for the high risk patients. Though improved outcomes in exacerbations with antibiotic choice based on such risk stratification has not yet been demonstrated in prospective controlled trials, this approach takes into account concerns of disease heterogeneity, antibiotic resistance and judicious antibiotic use in exacerbations

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2528209
Provided by: PubMed Central

Suggested articles

Citations

  1. (2002). A comparison of gemifl oxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther,
  2. (2002). Acquisition of a new bacterial strain and occurrence of exacerbations of chronic obstructive pulmonary disease.
  3. (2000). Acute exacerbation of COPD: factors associated with poor treatment outcome.
  4. (2004). Acute exacerbations of chronic bronchitis: new developments concerning microbiology and pathophysiology – impact on approaches to risk stratifi cation and therapy. Infect Dis Clin North Am, 18:861–82, ix.International
  5. (2001). Acute exacerbations of chronic bronchitis. What role for the new fl uoroquinolones? Drugs Aging,
  6. (2000). Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fi brinogen and serum IL-6 levels. Thromb Haemost,
  7. (2002). Acute exacerbations of COPD: A “multipronged” approach.
  8. (1993). Air pollution and emergency room admissions for chronic obstructive pulmonary disease: a 5-year study.
  9. (2000). Air pollution and mortality in a cohort of patients with chronic obstructive pulmonary disease: a time series analysis.
  10. (2000). Airway infl ammation and etiology of acute exacerbations of chronic bronchitis.
  11. (1987). Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.
  12. (2001). Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: a re-evaluation of previously published data of a placebo-controlled randomized study. Pulm Pharmacol Ther,
  13. (2006). Antibiotic treatment and factors infl uencing short and long term outcomes of acute exacerbations of chronic bronchitis.
  14. (2007). Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy.
  15. (2000). Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD.
  16. (2006). Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev,
  17. (1995). Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis.
  18. (1997). Antigenic characterization and analysis of the human immune response to outer membrane protein E of Branhamella catarrhalis. Infect Immun,
  19. (2004). Antimicrobial treatment guidelines for acute bacterial rhinosinusitis 2004. Otolaryngol Head Neck Surg,
  20. (2004). Bacteria in exacerbations of chronic obstructive pulmonary disease. Phenomenon or epiphenomenon? Proc Am Thorac Soc,
  21. (1996). Basophil-bound IgE and serum IgE directed against Haemophilus infl uenzae and Streptococcus pneumoniae in patients with chronic bronchitis during acute exacerbations.
  22. (1998). Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation.
  23. (1999). Bronchoalveolar infl ammation after exposure to diesel exhaust: comparison between unfi ltered and particle trap fi ltered exhaust. Occup Environ Med,
  24. (2007). Bronchoscopic validation of the signifi cance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease.
  25. (2003). Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J, 10(Suppl B):3B–32B.
  26. (2003). Chronic Obstructive Pulmonary Disease Data Fact Sheet,
  27. (2003). Chronic obstructive pulmonary disease. 6: The aetiology of exacerbations of chronic obstructive pulmonary disease.
  28. (1969). Course and prognosis of chronic obstructive lung disease. A prospective study of 200 patients.
  29. (1998). Diesel exhaust particles stimulate human airway epithelial cells to produce cytokines relevant to airway infl ammation in vitro.
  30. (2000). Do bacteria cause exacerbations of COPD?
  31. (1998). Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.
  32. (1994). Effect of nitrogen dioxide and sulphur dioxide on airway response of mild asthmatic patients to allergen inhalation.
  33. (2001). Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis.
  34. (2005). Haemophilus infl uenzae from patients with chronic obstructive pulmonary disease exacerbation induce more infl ammation than colonizers.
  35. (2001). Health status deterioration in patients with chronic obstructive pulmonary disease.
  36. (2000). Infectious etiology of acute exacerbations of chronic bronchitis.
  37. (2007). Initiative for Obstructive Lung Disease.
  38. (1998). Low grade rhinovirus infection induces a prolonged release of IL-8 in pulmonary epithelium.
  39. (2001). Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study.
  40. (2001). Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence.
  41. (2005). Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response.
  42. (2003). Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD.
  43. (2004). New developments in the pathogenesis of acute exacerbations of chronic obstructive pulmonary disease. Curr Opin Infect Dis,
  44. (2001). Once daily oral ofl oxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial.
  45. (2003). Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease.
  46. (2006). Pathogenesis of bacterial exacerbations of COPD.
  47. (2000). Patients with chronic obstructive pulmonary disease are at increased risk of death associated with urban particle air pollution: a case-crossover analysis.
  48. (2002). Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis
  49. (2005). Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis,
  50. (2007). Procalcitonin-guided antibiotic therapy in COPD exacerbations: closer but not quite there.
  51. (2002). Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.
  52. (2000). Relationship of sputum color to nature and outpatient managment of acute exacerbations of COPD.
  53. (2003). Resolution of bronchial infl ammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis.
  54. Respir Crit Care Med,
  55. (2005). Respiratory syncytial virus infection in elderly and high–risk adults.
  56. (2001). Respiratory viruses, symptoms, and infl ammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease.
  57. (2006). Role of nontypeable Haemophilus infl uenzae in exacerbations and progression of chronic obstructive pulmonary disease. Curr Opin Pulm Med,
  58. (2007). Salmeterol and fl uticasone propionate and survival in chronic obstructive pulmonary disease.
  59. (2002). Sequence stability of the gene encoding outer membrane protein P2 of nontypeable Haemophilus infl uenzae in the human respiratory tract.
  60. (2004). Short-term and long-term outcomes of moxifl oxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis.
  61. (2004). Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.
  62. (2004). Strain specifi c immune response to Haemophilus infl uenzae in chronic obstructive pulmonary disease.
  63. (2005). Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev,
  64. (2007). Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD.
  65. (2001). The effi cacy of moxifl oxacin in acute exacerbations of chronic bronchitis: a Spanish physician and patient experience.
  66. (1999). The infection-free interval: its use in evaluating antimicrobial treatment of acute exacerbation of chronic bronchitis. Clin Infect Dis,
  67. (1986). The need for chest roentgenograms in adults with acute respiratory illness.
  68. (2000). The role of bacteria in exacerbations of COPD. A constructive view.
  69. (2003). Time course of recovery of health status following an infective exacerbation of chronic bronchitis.
  70. (2000). Toward a consensus defi nition for COPD exacerbations.
  71. (2003). Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis,
  72. (2006). Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease.
  73. (1998). Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir Med,

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.